All Natural ingredient Pharmaceuticals for TheraCORE50

The Chinese National Drug Administration Bureau approved of this product for mass production on April 29, 2000 (Reference: Section 1, Document 1). This approval was given after two years of limited manufacture and testing in hospitals starting with the granting of a limited approval by the same agency of the Chinese Government on January 9, 1998 (Reference: Section 1, Document 2).

Our Partner company, Xing Ling, was awarded the "Touch Project" Certificate for the Company
's work on Ginko Biloba by the Science and Technology Ministry of the People's Republic of China on April 30, 1999 This is China's highest award for scientific achievement and has been previously been given to the Nuclear Weapons Development Project. 

Since receiving the approval for mass production more than 50,000 patients have been treated with, and no significant side effects have een reported other than mild stomach upset in a very few patients. This experience supplements the prior experience with Thera CORE 30 which the company started selling in China in 1994. Four million packages were sold in 2000.

There are more than 75 commercial Ginko Biloba product in the world (Reference: Section 5, Page 3.2). However, our Thera CORE series products were deemed to be sufficiently unique so that United States Patent Number 6,030,621. The abstract states "the invention provides different compositions extracted from Ginko Biloba leaves
..."

A phase I study was conducted in China on 15 healthy adult volunteers age 23 to 50 years. The volunteers ingested 1, 2 and 3 grams of TheraCORE 50 three times a day for 6 weeks showed no statistically significant (p>0.05) difference between baseline and 2-week, 4-week and 6-weeks in any of the physical, hematology, clinical chemistry, urinalysis, stool examination and ECGs performed (Reference: Section 5, Page 3-4 & 5).

A 6-week comparative phase II trial was conducted in four centers in China on 453 patients with either angina pectoris or vertigo related to mild cerebrovascular atherosclerois. Two separate trials, one for each indication were conducted. 243-patients age 19 to 70 years with angina were randomized and 213 and 30 were assigned to double-blind and open-label portion of the study, respectively. Studies compared TheraCORE 50 to Bai Lu Da. Bai Lu Da is a Ginkgo Biloba preparation used in China to treat angina. TheraCORE 50 was effective in treating angina pectoris: a significantly greater percentage of patients taking GBE 50 (38.2%) reported a markedly effective result compared to patients taking Bai Lu Da (15.6%). 210-patients age 18 to 70 years with vertigo related to mild cerebrovascular artherosclerosis were randomized and 150 and 60 were assigned to double-blind and open-label portion of the study, respectively. Studies compared TheraCORE 50 to Dan Qi Pian. Dan Qi Pian is a proprietary Traditional Chinese Medicine combination product containing 
Dan Sheng and Shan Qi that is used in China to treat verigo. TheraCORE 50 was effective in treating cerebral arteriosclerotic vertigo: a significantly greater percentage of patients taking TheraCORE 50 (77.2%) reported disappearence in stabbing head pain compared to patients taking Dan Qi Pian (21.5%) 

Clinical trails and one animal trial of GBE 50 are reported in Chinese Traditional Medicine, journal in 1998 (Reference: Section 4). Abstracts of the clinical trials performed by third parties to Xing Ling follow. 
......